<DOC>
	<DOCNO>NCT01423656</DOCNO>
	<brief_summary>The principal aim study obtain safety , tolerability pharmacokinetic data LEO 29102 administer cutaneously single multiple dos healthy subject . The study divide one single dose part , one part compare pharmacokinetics gender one multiple dose part .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetic Study Healthy Subjects Dermal Application LEO 29102</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Subjects Caucasian male females 18 55 year age body mass index ( BMI ) 18.0 30.0 kg/m2 inclusive . Subjects must good health , determine medical history , physical examination , 12lead electrocardiogram ( ECG ) clinical laboratory evaluation Subjects suffer , show sign eczema skin lesion . Subjects still participate clinical study ( e.g . attend followup visit ) participate clinical study involve administration investigational drug ( new chemical entity ) , market drug within past 3 month prior first dose occasion . Subjects significant history drug allergy determine Investigator . Subjects know immunocompromised state due treatment immunosuppressive drug due history disease lead immunocompromised status .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>